Skip to main content
Log in

Effects of Pioglitazone and Insulin on Tight Glycaemic Control Assessed by the Continuous Glucose Monitoring System

A Monocentric, Parallel-Cohort Study

  • Short Communication
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

References

  1. The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86

    Article  Google Scholar 

  2. United Kingdom Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type II diabetes (UKPDS 33). Lancet 1998; 352: 837–53

    Article  Google Scholar 

  3. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type II diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321(7258): 405–12

    Article  PubMed  CAS  Google Scholar 

  4. Manley S. Haemoglobin A1c: a marker for complications of type II diabetes: the experience from the UK Prospective Diabetes Study (UKPDS). Clin Chem Lab Med 2003; 41(9): 1182–90

    Article  PubMed  CAS  Google Scholar 

  5. Ceriello A. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabet Med 1998; 15: 188–93

    Article  PubMed  CAS  Google Scholar 

  6. Bastyr EJ, Stuart CA, Brodows RG, et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HBA1c. IOEZ Study Group. Diabetes Care 2000; 23: 1236–41

    Article  PubMed  CAS  Google Scholar 

  7. Shaw JE, Hodge AM, de Courten M, et al. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 1999; 42(9): 1050–4

    Article  PubMed  CAS  Google Scholar 

  8. Lefebre PI, Scheen AJ. The postprandial state and risk of cardiovascular disease. Diabet Med 1998; 15Suppl. 4: S63–8

    Article  Google Scholar 

  9. Diamant M, Heine RJ. Thiazolidinediones in type II diabetes mellitus: current clinical evidence. Drugs 2003; 63(13): 1373–405

    Article  PubMed  CAS  Google Scholar 

  10. Rosenblatt S, Miskin B, Glazer NB, et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type II diabetes mellitus. Coron Artery Dis 2001; 12: 413–23

    Article  PubMed  CAS  Google Scholar 

  11. Genuth S. Insulin use in NIDDM. Diabetes Care 1990; 13(12): 1240–64

    Article  PubMed  CAS  Google Scholar 

  12. Amin R, Ross K, Acerini CL, et al. Hypoglycemia prevalence in prepubertal children with type 1 diabetes on standard insulin regimen: use of continuous glucose monitoring system. Diabetes Care 2003; 26(3): 662–7

    Article  PubMed  Google Scholar 

  13. Aussedat B, Dupire-Angel M, Gifford R, et al. Interstitial glucose concentration and glycemia: implications for continuous subcutaneous glucose monitoring. Am J Physiol Endocrinol Metab 2000; 278(4): E716–28

    PubMed  CAS  Google Scholar 

  14. Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care 2001; 24(12): 2030–4

    Article  PubMed  CAS  Google Scholar 

  15. Gross TM, Bode BW, Einhorn D, et al. Performance evaluation of the Mini Med continuous glucose monitoring system during patient home use. Diabetes Technol Ther 2000; 2(1): 49–56

    Article  PubMed  CAS  Google Scholar 

  16. Kerr D. Continuous blood glucose monitoring: detection and prevention of hypoglycemia. Int J Clin Pract Suppl 2001; 123: 43–6

    PubMed  Google Scholar 

  17. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995 Feb; 18(2): 258–68

    Article  PubMed  CAS  Google Scholar 

  18. Wei M, Gaskill SP, Haffner SM, et al. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998 Jul; 21(7): 1167–72

    Article  PubMed  CAS  Google Scholar 

  19. Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004; 21: 568–76

    Article  PubMed  CAS  Google Scholar 

  20. Campbell IW. Long-term glycemic control with pioglitazone in patients with type 2 diabetes. Int J Clin Pract 2004; 58(2): 192–200

    Article  PubMed  CAS  Google Scholar 

  21. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type II diabetes. Diabetes Care 2000; 23: 1605–11

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by Takeda Pharma GmbH, Germany. The authors have no conflicts of interest directly relevant to the content of this article.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jung, W., Jung, S. Effects of Pioglitazone and Insulin on Tight Glycaemic Control Assessed by the Continuous Glucose Monitoring System. Clin. Drug Investig. 25, 347–352 (2005). https://doi.org/10.2165/00044011-200525050-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200525050-00008

Keywords

Navigation